In Depth 11 Sep 2023 Evolving biotech funding trends: VCs lead new series B deals, but early-stage deals require insider support With biotech funding trends always evolving, HSBC Innovation Banking’s inaugural Venture Healthcare Report lays out the trends seen in the first half (1H) of 2023, where valuations underwent a necessary reset, and venture capitalists emerged from their cautious stance, eventually embarking on a fresh wave of investments. However, an overall decline in investment was still […] September 11, 2023 - 5 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 4 Sep 2023 The biggest private biotech investments in August 2023 The companies Genesis Therapeutics, ADARx Pharmaceuticals, and Abcuro bagged the biggest biotech investments in August 2023. Around the world, companies focused on immunology, genetic disorders, and metabolic disorders attracted the biggest funding rounds. Overall, quite a lot of biotech fundraising took place in August 2023. As always, there were some big rounds within the U.S. […] September 4, 2023 - 3 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Podcast 25 Aug 2023Beyond Biotech podcast 60 – The cost of research On this week’s podcast, we have a conversation with Dr Jack Scannell, CEO of Etheros Pharmaceuticals Corp. Scannell recently co-authored a paper on the expenses related to clinical research and the factors that underly the translational failure of inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) in oncology. Costs and Causes of Oncology Drug Attrition […] August 25, 2023 Share WhatsApp Twitter Linkedin Email
Best in Biotech 17 Aug 2023 Six Toronto-based biotech companies to watch this year The capital city of the Canadian province of Ontario, Toronto, is home to the Discovery District, a commercial hub that sees biotech and healthcare innovations and companies at its prime. Having witnessed the largest growth in tech jobs in North America between 2015 and 2020, Toronto, like Vancouver, is a significant contributor towards Canada’s life […] August 17, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 2 Aug 2023 The biggest private biotech investments in July 2023 The companies Sinotau, Septerna, and Kriya Therapeutics bagged the biggest biotech investments in July 2023. Around the world, drug discovery and oncology attracted the biggest funding rounds. Biotech fundraising seemed to dry up a little bit in July 2023 compared to previous months, but that’s only to be expected as the summer kicks in. And, […] August 2, 2023 - 3 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jul 2023 New CHAIN Biotech funding to aid CADD therapeutic platform CHAIN Biotechnology Limited has developed a therapeutic approach based on engineering a probiotic strain of Clostridium to deliver oral vaccines and therapeutics. Its Clostridium Assisted Drug Development platform (CADD) technology is a live therapeutic that employs a triple mode of action, incorporating mucosal and systemic immune responses alongside microbiome enhancement, and is delivered via stable, […] July 28, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jul 2023 Medicxi announces $400M fund for life science companies Medicxi, a European life sciences investment firm, has launched its $400 million Medicxi IV fund. The new fund will support companies with clear product visions to deliver transformative therapies for patients. Medicxi’s investments have resulted in the development of several marketed and late-stage development drugs, including Daratumumab (Genmab/Johnson & Johnson), Blincyto (Amgen), Alunbrig (Takeda), Voquezna […] July 27, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jul 2023 Molecure raises $12M and gets FDA clearance for pulmonary sarcoidosis trial Molecure S.A. has received clearance from the U.S. Food and Drug Administration (FDA) on its Investigational New Drug (IND) application to conduct phase II clinical testing of OATD-01. The announcement follows the company closing a secondary public offering and entering into subscription agreements for all 2,776,000 H-shares offered by way of private placement, within the […] July 25, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jul 2023 Crescendo Biologics raises $32M and expands cancer trial Crescendo Biologics Ltd, a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, has announced that it plans to augment the ongoing phase 1b clinical trial of CB307 through the addition of a new pembrolizumab (anti-PD-1) combination expansion cohort. Additional financing of $32 million has been secured with the support of all major […] July 25, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jul 2023 Westlake launches $450M fund for LA biotechs Westlake Village BioPartners has launched its third fund of $450 million to incubate and grow early stage next-generation biotechnology companies in the Los Angeles region and beyond. The new fund will be managed by founding managing director Beth Seidenberg, managing director Mira Chaurushiya, and David Allison, who was recently appointed managing director. “This new fund […] July 17, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Jul 2023 BioGeneration Ventures closes BGV Fund V at €150M BioGeneration Ventures (BGV), an early-stage venture capital company in European biopharma, has closed its BGV V fund at €150 million ($167.9 million), its largest fund since launching its first fund in 2006. BGV V was oversubscribed, with demand from both existing and new investors, with existing investors Eli Lilly and Company, Novo Holdings and Bristol […] July 14, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 13 Jul 2023 Gold rush over: what happens to biotech now that venture capital is out of reach? If you were to look back just a little over two years ago to the start of 2021, then putting money into a biotech company seemed like a pretty safe bet. After all, the COVID-19 pandemic had shined a positive spotlight on the biopharmaceutical industry, and initial public offerings (IPOs) were booming. But the last […] July 13, 2023 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email